←
AlamarBio317 posts
AlamarBio avatar

AlamarBio

@AlamarBio

alamarbio.com

◷ Joined May 2022▧ 277 Photos and videos
AlamarBio avatar
AlamarBio@AlamarBio·Nov 17

What can the next generation of proteomics reveal about the brain?   On November 25, join Alamar Biosciences online for Proteomics in Brain Health and Beyond, a virtual symposium exploring how ultrasensitive, multiplex proteomics powered by NULISA™ Technology is advancing research into neurodegeneration, inflammation, aging, and beyond.   Hear from 12 leading researchers and experts, including keynote speaker Dr. Carlos Cruchaga, as they share the latest research, emerging applications, and new perspectives on biomarker discovery.   Join us live and discover what's next in proteomics and brain health. Register now: na2.hubs.ly/H091ZH40   #NULISA #Proteomics #Neurology #Biomarkers #Neurodegeneration

0:11
AlamarBio avatar
AlamarBio@AlamarBio·Nov 17

A significant milestone in Alzheimer's biomarker research! A new study published in JAMA demonstrates the performance of an ultrasensitive NULISA™-based eMTBR-tau immunoassay.   Co-led by Nicholas J. Ashton, PhD, (Banner Sun Health) the study evaluated 728 participants across four independent cohorts, demonstrating strong associations between plasma eMTBR-tau levels and advanced neurofibrillary tangle pathology assessed through brain autopsy and tau PET.   The NULISA™ eMTBR-tau assay achieved AUCs of 0.96–0.99 for identifying regional tau-PET positivity and showed strong correlation with mass spectrometry measurements (ρ = 0.93), using just 35 µL of plasma, approximately 43 times less than the mass spectrometry method evaluated.   These findings underscore the potential of NULISA™ technology to enable ultrasensitive measurement of emerging blood-based biomarkers, supporting advances in Alzheimer's disease research and further investigation of biological disease staging.   Read the publication: na2.hubs.ly/H091Fxy0   #AlzheimersResearch #Biomarkers #NULISA #eMTBR #AlzheimersDisease #Proteomics

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Nov 16

NULISA data featured in 46 presentations at #CTAD2026: 10 oral presentations and 36 posters from more than 30 academic, clinical, and biopharma groups across 10 countries. The research covers brain-derived and CNS-selective p-tau217, biomarker readouts from interventional trials including Auτonomy, FINGER, and APOLLOE4, plasma proteomic responses to lecanemab and ARIA, synaptic and inflammatory signatures, and conditions beyond Alzheimer’s disease such as CTE, TDP-43 pathology, and primary tauopathies. Download the full listing here: na2.hubs.ly/H08_XfP0 Talks run Nov 16 to 19 in the Ballroom (4th floor). Posters are across Sessions 1 to 3 in the Atrium and Gloucester rooms (3rd floor). Please stop by and talk with the presenters about their work! Alamar colleagues will be onsite and welcome discussion about your Alzheimer's research needs.

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Nov 11

Can proteomics help measure biological aging and reveal whether interventions are making a difference?   From biological aging clocks to clinical trials and population cohorts, proteomics is opening new possibilities in geroscience.   In our upcoming webinar with GEN, Dr. Michael Corley (UC San Diego), Prof. Claire Steves (King's College London), and Dr. Xiao-Jun Ma (Alamar Biosciences) will explore how ultra-sensitive, multiplexed proteomics is advancing aging research.   Hear how proteomic aging clocks can predict age-related health outcomes, how clinical trial data can reveal the effects of interventions, and how longitudinal proteomics can uncover new insights into aging, resilience, and disease risk.   💡 Stay for a live Q&A with both speakers 🔗 Register now: na2.hubs.ly/H08Z1gZ0   #NULISA #Proteomics #Geroscience #AgingResearch #Biomarkers #Webinar

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Nov 9

Discover what’s possible when immune profiling goes beyond individual cytokines.   Join Caroline Chan, PhD (Alamar Biosciences) and Katharina Stracke, PhD (GeneWorks) for an upcoming webinar exploring how the NULISAseq™ Immune 340 Panel is advancing immune profiling and opening new opportunities for biomarker discovery and treatment-response research across autoimmunity and cancer immunology.   📍ANZ researchers: stay to the end to learn how to apply for the Immune 340 Pilot Program. Register now: na2.hubs.ly/H08SrR70   #NULISA #Proteomics #Immunology #Autoimmunity #ImmunoOncology

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Nov 4

Why can two patients with the same diagnosis experience very different disease trajectories?   A new collaboration between Alamar Biosciences and GSK will use NULISA™ to explore that question at scale.   More than 60,000 serum samples will be analyzed using NULISAseq™ Immune 340 and Neuro 220 to investigate protein signatures associated with disease progression, biological subtypes, and treatment response across multiple disease areas, helping uncover the biology underlying differences among patients with the same clinical diagnosis.   Read the full announcement: na2.hubs.ly/H08Pjbx0

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Nov 2

A major new study is taking neurodegenerative disease research to population scale.   Alamar Biosciences and Nightingale Health ( @NgaleHealth ) are launching the UK-PRISM vanguard study with UK Biobank ( @UK_Biobank ), measuring hundreds of blood-based protein biomarkers across 80,000 samples using NULISA™.   The resulting data will help researchers investigate the earliest molecular indicators of Alzheimer’s disease, Parkinson’s disease, rare dementias, and other neurodegenerative conditions, while creating a powerful open-access resource for the global research community.   Read the announcement: na2.hubs.ly/H08LG2C0 @lifearc1 @AlzResearchUK #proteomics #precisionproteomics #alzheimers

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Oct 30

A meaningful day for Alamar in San Francisco. 💜 Last weekend, our team joined the Walk to End Alzheimer’s as a proud sponsor, walking alongside colleagues, families, friends, and the broader community in support of a future without Alzheimer’s disease. It’s a cause closely connected to our mission to advance human health by powering precision proteomics and enabling the earliest detection of disease. Thank you to the Alzheimer’s Association® and everyone who walked, volunteered, donated, and supported this year’s event. Together, every step makes a difference.

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Oct 29

New research is revealing a broader proteomic signature of ALS beyond neurofilament alone.   In a new Nature Communications study, Jonathan Glass, MD, and the team at Emory University used NULISA™ Technology to profile neurological and inflammatory proteins in plasma and develop a 10-protein blood signature spanning markers including NEFL, pTau-181, FOLR1, TREM1, and VEGFA.   The signature achieved 98.3% balanced accuracy in an independent validation cohort, outperforming NEFL alone and capturing disease-associated signals that could help distinguish challenging ALS presentations.   By enabling ultrasensitive, multiplex profiling across neurological and inflammatory proteins, NULISA™ is helping researchers uncover biomarker signatures that may otherwise be missed.   Read the full press release: na2.hubs.ly/H08JD1f0 See what NULISA™ helped uncover in the study: na2.hubs.ly/H08JD1j0   #NULISA #ALS #Proteomics #Biomarkers #Neurodegeneration

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Oct 29

“There had to be a better way to do proteomics.” Recently named the COO winner of the 2026 San Francisco Business Times C-Suite Awards, Steve Chen, Co-Founder and Chief Operating Officer of Alamar Biosciences, shared more about the vision that has shaped his work at Alamar and his perspective on the future of proteomics. From the beginning, Steve has focused on a longstanding challenge in the field: accessing low-abundance proteins with both high sensitivity and high multiplexing. Today, NULISA™ is giving researchers new ways to explore the proteome. But for Steve, the bigger story is where that capability can take the field next. As more of the proteome becomes accessible to measurement, so does the potential to uncover new biological insights, advance biomarker research, and deepen our understanding of human health and disease. Read more about Steve’s journey in this C-Suite Awards profile: na2.hubs.ly/H08HWYJ0 #Proteomics #PrecisionProteomics #NULISA #Biomarkers #LifeSciences #AlamarBiosciences

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Oct 28

Join Alamar Biosciences and the IRCCS Regina Elena National Cancer Institute on November 6 in Rome, Italy, for a half-day hybrid scientific seminar exploring the application of NULISA™ Technology in oncology and immuno-oncology research.   Hear from leading researchers and experts Dr. Matteo Gastaldi of Fondazione Mondino, Dr. Matteo Allegretti of IRCCS Regina Elena National Cancer Institute, Drs. Mathias Holpert and Marijana Rucevic of Alamar Biosciences, and Dr. Lucy Goudswaard of the University of Bristol as they share research and case studies demonstrating how ultrasensitive, multiplex proteomics can advance biomarker profiling across oncology, immuno-oncology, inflammation, and neuroinflammation.   Register today: na2.hubs.ly/H08DgvL0 #NULISA #Proteomics #Oncology #ImmunoOncology #Biomarkers #PrecisionProteomics #Seminar

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Oct 26

Another incredible ARGOnaut Summit in the books! This time in Napa, California.   Thank you to our speakers and attendees for two inspiring days of NULISA™ research, scientific exchange, and collaboration. Together, the ARGOnaut community continues to push beyond the known, uncover new possibilities, and take precision proteomics to new frontiers.   We look forward to bringing our ARGOnauts together again next year as we continue exploring what’s possible. 🚀

Post attachment
AlamarBio avatar
AlamarBio@AlamarBio·Oct 21

New GenomeWeb coverage takes a closer look at Carlos Cruchaga and his team’s recent findings on plasma biomarker changes during lecanemab treatment.   Using NULISAseq™, the team identified 34 proteins that changed significantly during treatment, revealing distinct trajectories across biomarkers associated with amyloid, tau, neuroinflammation, and neurodegeneration.   The GenomeWeb story digs deeper into these findings, including the team’s efforts to investigate biomarkers that could help predict amyloid clearance and further characterize treatment response.   Read the full story: na2.hubs.ly/H08xjrH0

AlamarBio avatar
AlamarBio@AlamarBio·Oct 19

We’re proud to sponsor the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), bringing together the global multiple sclerosis community in Toronto.    As researchers and clinicians gather to share the latest advances in MS and related disorders, we look forward to connecting with the community and discussing how ultrasensitive proteomics can help uncover new insights into neurological disease biology.   Visit Alamar Biosciences at Booth 129 to meet our team and learn how NULISA™ is advancing biomarker research in MS and beyond.   Learn more: na2.hubs.ly/H08rQWf0   #MSToronto2026 #MultipleSclerosis #MSResearch #Neurology #Proteomics #Biomarkers #NULISA #AlamarBiosciences

0:17
AlamarBio avatar
AlamarBio@AlamarBio·Oct 12

Only 3 days remain to apply for the NULISA™ Immunology Grant Program! Apply now: na2.hubs.ly/H08kHlT0   Four selected research projects will receive access to the NULISAseq™ Immune 340 Panel, including analysis of 86 samples through Alamar Biosciences’ Technology Access Program (TAP). Leverage ultrasensitive, multiplex proteomics to explore key immune pathways, identify potential biomarkers, and uncover new insights into immune-related disease biology.   Applications close Thursday, October 15 at 11:59 PM PT. Submit your application today before the deadline. #ResearchGrant #NULISA #AlamarBiosciences #Immunology #Proteomics #PrecisionProteomics #Grant

0:10